Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome

NCT07770282 on ClinicalTrials.gov · last registry update 2026-08-18

Registered but not yet open, with 600 participants planned. Due to report 30 July 2030, alongside 5 other tracked readouts that quarter. Primary outcome, as filed: Change in QRISK3 (QResearch Cardiovascular Risk Prediction Algorithm Version 3),10-year cardiovascular risk score. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for metabolic syndrome and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: All India Institute of Medical Sciences, Bhubaneswar
Sponsor type: Other
Enrollment: 600
Started: 2026-12-01
Primary completion: 2030-07-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in QRISK3 (QResearch Cardiovascular Risk Prediction Algorithm Version 3),10-year cardiovascular risk score

Conditions studied

Schizophrenia Disorder · Metabolic Syndrome · Antipsychotic-induced Weight Gain · Cardiovascular Risk · Insulin Resistance

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.